Main Subject - Business

There are lots of so-called “measures” that people choose to monitor business results. Some are good, some bad and some downright ugly! This

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

is one of the most colossal mistakes I see people making with performance measures: to claim as a performance measure something that absolu

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

tely is not a measure of performance at all.

Here are three of the so-called performance measures that I really dislike most:

"win the Bla

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

hBlah Award"

The award might be a customer service award, or environmental award, or workplace health and safety award. Why do I dislike aw

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

ards as measures? The winning of an award is an event, and can’t give regular, ongoing feedback that can inform decision making and improvem

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

ent - to use it as evidence of business performance assumes that the criteria for the award correlate directly to the business’s priorities

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

and strategy. And just think about the kind of behaviour and culture this kind of "measure" would encourage... everyone aiming to impress th

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

e judges of the award and taking their eyes off their real stakeholders.

"complete BlahBlah Project by June 2007"

Projects such as impleme

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

nting a customer relationship management system, or upgrading a maintenance facility, or running a new employee training program are typical

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

ly put in the KPI column of business plans. They are next to useless as evidence or feedback about business performance. Finishing a project

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

by a particular date is an action, not an outcome, and thus provides no evidence whatsoever of the result that the project should have achie

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

ved. But they are the most common type of "measure". My theory is that it's because we are an activity culture - we have been duped into the

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

false belief that as long as we do things (and finish them on time and to budget) then we have succeeded. A little more scientific thinking

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

would go a long way: we need to use measures to test our hypotheses that the actions we have chosen in fact do produce the results we inten

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

ded. So in reality, measures like these are actually strategies - the means we have chosen to achieve the results we want for our business.

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

"Annual BlahBlah Survey"

The survey could be an employee survey or a market survey or a community reputation survey - who knows? Irrespect

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

ive, surveys are just data collection processes, not measures. The measures come from the data the survey collects and the measures must be

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

very clearly designed and defined in order to ensure the survey collects the right data. Way too much money is wasted on surveys that ask ir

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

relevant questions, and collect data that is never used. I guess having my foundations as a survey statistician makes me particularly frustr

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

ated by measures of this type. I'd just love to see more people demonstrating that they can discern the difference between data and measures

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.mainsubjects.org.ua/article/20842/mainsubjects-Performance-Measures--The-Good-The-Bad-And-The-Ugly.html">Performance Measures - The Good, The Bad And The Ugly</a>

BB link (for phorums):
[url=http://www.mainsubjects.org.ua/article/20842/mainsubjects-Performance-Measures--The-Good-The-Bad-And-The-Ugly.html]Performance Measures - The Good, The Bad And The Ugly[/url]

However, until recently, the use of Excel for medical billing analysis has been limited because of the difficulty to produce effective ad hoc reports and inability to export data into Excel. Vericle lifts the limitation with its integrated medical billing reporting and a 2-step Excel export capability.

Certain responsibilities lie with the shipper for all LTL and TL shipments. These responsibilities apply across the board with all freight carrier companies. Proper packaging, address labeling, shipment loading and unloading, and proper shipment documents (BOL provided to you by us) are required by all carriers and are the responsibility of the shipper.

I read through the copy on The Rich Jerk site, and found it a little entertaining...

Tags

Links

Main Subject - Performance Measures - The Good, The Bad And The Ugly

Related Articles: